1. Ahlgren, JD (1996). Epidemiology and risk factors in pancreatic cancer. Semin Oncol 23: 241–250.
2. Barber, MD, Wigmore, SJ, Ross, JA & Fearon, KCH (1997). Eicosapentaenoic acid attenuates cachexia associated with advanced pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 57: 204
3. Beck, SA, Smith, KL & Tisdale, MJ (1991). Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51: 6089–6093.
4. Cohn, SH, Vartsky, D, Vaswani, AN, Sawitsky, A, Rai, K, Gartenhaus, W, Yasumura, S & Ellis, KJ (1982). Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer 4: 107–119.
5. DeWys, WD, Begg, C, Lavin, PT, Band, PR, Bennett, JM, Bertino, JR, Cohen, MH, Douglass, HO, Engstrom, PF, Ezdinli, EZ, Horton, J, Johnson, GJ, Moertel, CG, Oken, MM, Perlia, C, Rosenbaum, C, Silverstein, MN, Skeel, RT, Sponzo, RW & Tormey, DC (1980). Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491–497.